Andrew Gengos - 24 Feb 2025 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Role
Chief Financial Officer
Signature
/s/ David Strauss, as Attorney-in-Fact for Andrew Gengos
Issuer symbol
TERN
Transactions as of
24 Feb 2025
Net transactions value
$0
Form type
4
Filing time
25 Feb 2025, 18:12:34 UTC
Previous filing
05 Sep 2024
Next filing
16 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TERN Stock Option (Right to Buy) Award $0 +750,000 $0.000000 750,000 24 Feb 2025 Common Stock 750,000 $3.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on the first anniversary measured from February 24, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.